Cargando…

Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer

PURPOSE: Physician Orders for Life-Sustaining Treatment (POLST) form is a legal document for terminally ill patients to make medical decisions with physicians near the end-of-life. A multicenter prospective study was conducted to evaluate the feasibility of POLST administration in actual oncological...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ho Jung, Jeon, Hyun Jeong, Chun, Sang Hoon, Jung, Hyun Ae, Ahn, Hee Kyung, Lee, Kyung Hee, Kim, Min-ho, Kim, Ju Hee, Cheon, Jaekyung, Kim, JinShil, Koh, Su-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790857/
https://www.ncbi.nlm.nih.gov/pubmed/30999720
http://dx.doi.org/10.4143/crt.2019.009
_version_ 1783458855573782528
author An, Ho Jung
Jeon, Hyun Jeong
Chun, Sang Hoon
Jung, Hyun Ae
Ahn, Hee Kyung
Lee, Kyung Hee
Kim, Min-ho
Kim, Ju Hee
Cheon, Jaekyung
Kim, JinShil
Koh, Su-Jin
author_facet An, Ho Jung
Jeon, Hyun Jeong
Chun, Sang Hoon
Jung, Hyun Ae
Ahn, Hee Kyung
Lee, Kyung Hee
Kim, Min-ho
Kim, Ju Hee
Cheon, Jaekyung
Kim, JinShil
Koh, Su-Jin
author_sort An, Ho Jung
collection PubMed
description PURPOSE: Physician Orders for Life-Sustaining Treatment (POLST) form is a legal document for terminally ill patients to make medical decisions with physicians near the end-of-life. A multicenter prospective study was conducted to evaluate the feasibility of POLST administration in actual oncological practice. MATERIALS AND METHODS: Patients with terminal cancer, age ≥ 20 years, and capable of communicating were eligible. The primary endpoint was the completion rate of POLST. Data about physicians’ or patients’ barriers were also collected. RESULTS: From June to December 2017, 336 patients from seven hospitals were eligible. Median patient age was 66 years (range, 20 to 94 years); 52.7% were male; and 60.4% had poor performance status. Primary cancer sites were hepato-pancreato-biliary (26.2%), lung (23.2%), and gastrointestinal (19.9%). Expected survival duration was 10.6±7.3 weeks, with 41.2% receiving hospice care, 37.9% showing progression after cancer treatment, and the remaining patients were under active treatment (15.8%) or initially diagnosed with terminal cancer (5.1%). POLST forms were introduced to 60.1% of patients, and 31.3% signed the form. Physicians’ barriers were reluctance of family (49.7%), lack of rapport (44.8%), patients’ denial of prognosis (34.3%), lack of time (22.7%), guilty feelings (21.5%), and uncertainty about either prognosis (21.0%) or the right time to discuss POLST (16.6%). The patients’ barriers were the lack of knowledge/understanding of POLST (65.1%), emotional discomfort (63.5%), difficulty in decision-making (66.7%), or denial of prognosis (14.3%). CONCLUSION: One-third of patients completed POLST forms, and various barriers were identified. To overcome such barriers, social engagement, education, and systematic support might be necessary.
format Online
Article
Text
id pubmed-6790857
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-67908572019-10-21 Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer An, Ho Jung Jeon, Hyun Jeong Chun, Sang Hoon Jung, Hyun Ae Ahn, Hee Kyung Lee, Kyung Hee Kim, Min-ho Kim, Ju Hee Cheon, Jaekyung Kim, JinShil Koh, Su-Jin Cancer Res Treat Original Article PURPOSE: Physician Orders for Life-Sustaining Treatment (POLST) form is a legal document for terminally ill patients to make medical decisions with physicians near the end-of-life. A multicenter prospective study was conducted to evaluate the feasibility of POLST administration in actual oncological practice. MATERIALS AND METHODS: Patients with terminal cancer, age ≥ 20 years, and capable of communicating were eligible. The primary endpoint was the completion rate of POLST. Data about physicians’ or patients’ barriers were also collected. RESULTS: From June to December 2017, 336 patients from seven hospitals were eligible. Median patient age was 66 years (range, 20 to 94 years); 52.7% were male; and 60.4% had poor performance status. Primary cancer sites were hepato-pancreato-biliary (26.2%), lung (23.2%), and gastrointestinal (19.9%). Expected survival duration was 10.6±7.3 weeks, with 41.2% receiving hospice care, 37.9% showing progression after cancer treatment, and the remaining patients were under active treatment (15.8%) or initially diagnosed with terminal cancer (5.1%). POLST forms were introduced to 60.1% of patients, and 31.3% signed the form. Physicians’ barriers were reluctance of family (49.7%), lack of rapport (44.8%), patients’ denial of prognosis (34.3%), lack of time (22.7%), guilty feelings (21.5%), and uncertainty about either prognosis (21.0%) or the right time to discuss POLST (16.6%). The patients’ barriers were the lack of knowledge/understanding of POLST (65.1%), emotional discomfort (63.5%), difficulty in decision-making (66.7%), or denial of prognosis (14.3%). CONCLUSION: One-third of patients completed POLST forms, and various barriers were identified. To overcome such barriers, social engagement, education, and systematic support might be necessary. Korean Cancer Association 2019-10 2019-04-18 /pmc/articles/PMC6790857/ /pubmed/30999720 http://dx.doi.org/10.4143/crt.2019.009 Text en Copyright © 2019 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
An, Ho Jung
Jeon, Hyun Jeong
Chun, Sang Hoon
Jung, Hyun Ae
Ahn, Hee Kyung
Lee, Kyung Hee
Kim, Min-ho
Kim, Ju Hee
Cheon, Jaekyung
Kim, JinShil
Koh, Su-Jin
Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
title Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
title_full Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
title_fullStr Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
title_full_unstemmed Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
title_short Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
title_sort feasibility study of physician orders for life-sustaining treatment for patients with terminal cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790857/
https://www.ncbi.nlm.nih.gov/pubmed/30999720
http://dx.doi.org/10.4143/crt.2019.009
work_keys_str_mv AT anhojung feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT jeonhyunjeong feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT chunsanghoon feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT junghyunae feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT ahnheekyung feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT leekyunghee feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT kimminho feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT kimjuhee feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT cheonjaekyung feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT kimjinshil feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer
AT kohsujin feasibilitystudyofphysicianordersforlifesustainingtreatmentforpatientswithterminalcancer